Not Tagged
Not Tagged
['prostate']
 good discussion on clinical endpoints with rpfs and os. great oral presentation. one question that remains is as we have newer therapeutics in prostate, does intensification that may lead to marrow toxicity and prevent further lines always lead to os even if has rpfs?
Assistant Director of Genitourinary Research at Sarah Cannon Research Institute at Tennessee Oncology. All tweets and views are my own.